Filing Flows

Filing Flows › Usana Health Sciences (USNA) › Q1 2026

Usana Health Sciences (USNA) Q1 2026 earnings results (first quarter 2026)

10-Q filed May 12, 2026

Usana Health Sciences (USNA) reported revenue of $250M for the first quarter 2026 (Q1 2026), +0.3% from a year earlier and +11% from the quarter before. Operating margin was 5.5%, net earnings $7.5M (3.0% of revenue).

Revenue$250M
Year over year+0.3%
Quarter over quarter+11%
Operating margin5.5%
Net earnings$7.5M

Usana Health Sciences, Q1 2026: revenue $250M (+0.3% year over year), operating margin 5.5%, net earnings $7.5M, operating cash flow $9.8M. The chart follows the revenue to costs, profit and cash.

Q1 2026AmountQ/QY/Y
Revenue$250M+11%+0.3%
Gross profit$191M+8%-3%
Operating profit$13.9M+263%-11%
Net earnings$7.5M—-20%
Operating cash flow$9.8M—-37%
Free cash flow$7.1M—-44%

What changed

Revenue was $250.2M in Q1 2026, roughly flat year over year and up 11% from the previous quarter.

Gross margin was 76.2%, down 2.7 points from Q1 2025. Operating profit was $13.9M, a 5.5% margin (down 0.7 points year over year). Operating profit fell $1.8M even though revenue rose $679K versus Q1 2025, so costs grew faster than sales. Operating expenses fell 2% while revenue was flat. Net earnings were $7.5M, down 20% year over year ($7.0M including minority interests, which bore $556K of losses). The effective tax rate was 55.0%.

Operating cash flow was $9.8M (down 37% year over year), 140% of net income including minority interests. Non-cash charges added back $8.3M of depreciation and amortization and $3.5M of share-based compensation. Working capital and other items used $8.9M. Capital expenditures of $2.6M left free cash flow of $7.1M.

Questions

What was Usana Health Sciences' revenue in the first quarter 2026?

Usana Health Sciences (USNA) reported revenue of $250M for the first quarter 2026 (Q1 2026), +0.3% from a year earlier and +11% from the quarter before.

Was Usana Health Sciences profitable in the first quarter 2026?

Operating profit was $13.9M (5.5% of revenue) and net earnings $7.5M.

Open the interactive Sankey →

Source: Usana Health Sciences 10-Q on SEC EDGAR.